Refining the predictors of risk for central nervous system involvement in patients with mantle cell lymphoma

References

• van Besien K, Ha CS, Murphy S, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998;91:1178–1184.
   PubMed Web of Science ®Google Scholar
• Hollender A, Kvaloy S, Nome O, et al. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 2002;13:1099–1107.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Magagnoli M, Frezza G, et al. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience. Leuk Lymphoma 1999;32:571–576.
   PubMed Web of Science ®Google Scholar
• Feugier P, Virion JM, Tilly H, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 2004;15:129–133.
   PubMed Web of Science ®Google Scholar
• Boehme V, Schmitz N, Zeynalova S, et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009;113:3896–3902.
   PubMed Web of Science ®Google Scholar
• Ferrer A, Bosch F, Villamor N, et al. Central nervous system involvement in mantle cell lymphoma. Ann Oncol 2008;19: 135–141.
   PubMed Web of Science ®Google Scholar
• Gill S, Herbert KE, Prince HM, et al. Mantle cell lymphoma with central nervous system involvement: frequency and clinical features. Br J Haematol 2009;147:83–88.
   PubMed Web of Science ®Google Scholar
• Oinonen R, Franssila K, Elonen E. Central nervous system involvement in patients with mantle cell lymphoma. Ann Hematol 1999;78:145–149.
   PubMed Web of Science ®Google Scholar
• Valdez R, Kroft SH, Ross CW, et al. Cerebrospinal fluid involvement in mantle cell lymphoma. Mod Pathol 2002;15:1073–1079.
   PubMed Web of Science ®Google Scholar
• Cheah CY, George A, Gine E, et al. Incidence, characteristics and outcome of CNS involvement in mantle cell lymphoma: a multicenter retrospective analysis from the European Mantle Cell Lymphoma Network. Haematologica 2012;97(Suppl. 1): Abstract 1112.
   Google Scholar
• Siegal T, Goldschmidt N. CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom?. Blood Rev 2012;26:97–106.
   PubMed Web of Science ®Google Scholar
• Dierickx D, Wlodarska I, Vanhentenrijk V, et al. Secondary central nervous system involvement in cyclin D1-negative mantle cell lymphoma. Leuk Lymphoma 2008;49:2365–2366.
   PubMed Web of Science ®Google Scholar
• Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:558–565.
   PubMed Web of Science ®Google Scholar
• Conconi A, Franceschetti S, Lobetti-Bodoni C, et al. Risk factors of central nervous system relapse in mantle cell lymphoma. Leuk Lymphoma 2013;54:1908–1914.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus Hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013–7023.
   PubMed Web of Science ®Google Scholar
• Delarue R, Haioun C, Ribrag V, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d’Etude des Lymphomes de l’Adulte. Blood 2013;121:48–53.
   PubMed Web of Science ®Google Scholar
• Craig FE, Ohori NP, Gorrill TS, et al. Flow cytometric immunophenotyping of cerebrospinal fluid specimens. Am J Clin Pathol 2011;135:22–34.
   PubMed Web of Science ®Google Scholar
• Hegde U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005;105:496–502.
   PubMed Web of Science ®Google Scholar
• Sancho J-M, Orfao A, Quijano S, et al. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era. Eur J Haematol 2010;85:321–328.
   PubMed Web of Science ®Google Scholar
• Ritchie DS, Seymour JF, Grigg AP, et al. The hyper-CVAD– rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol 2007;86:101–105.
   PubMed Web of Science ®Google Scholar
• Tam CS, Bassett R, Ledesma C, et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009;113:4144–4152.
   PubMed Web of Science ®Google Scholar
• Wang M, Rule SA, Martin P, et al. Interim results of an international, multicenter, phase 2 study of Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), in relapsed or refractory mantle cell lymphoma (MCL): durable efficacy and tolerability with longer follow-up. Blood 2012;120(Suppl. 1): Abstract 904.
   Google Scholar
• Davids MS, Roberts AW, Anderson MA, et al. The BCL-2-specific BH3-mimetic ABT-199 (GDC-0199) is active and well-tolerated in patients with relapsed non-Hodgkin lymphoma: interim results of a phase I study. Blood 2012;120(Suppl. 1): Abstract 304.
   PubMed Web of Science ®Google Scholar